Get to know our clinical trials
Trial of immunotherapy combinations in adult participants with previously untreated advanced non-small cell lung cancer (NSCLC) with elevated PD-L1 expression.
THE OBJECTIVE OF THIS TRIAL IS TO ENSURE THAT THE COMBINATION IMMUNOTHERAPY* REGIMENS TESTED ARE EFFECTIVE AND SAFE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC).
Specialist
Medical Oncology Department
Navarre headquarters
Technical Summary
- PHASE 1B/2, MULTICENTER, OPEN-LABEL, OPEN-LABEL, PLATFORM STUDY FOR THE SELECTION OF IMMUNOTHERAPY COMBINATIONS IN ADULT PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH ELEVATED PD-L1 EXPRESSION.
- Code EudraCT: 2023-508730-34
- Protocol number: SPLFIO-174
- Promoter: Laboratorios Servier, S.A.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.